Chapter/Section Purchase

1 Study Coverage
1.1 Homozygous Familial Hypercholesterolemia Treatment Product Introduction
1.2 Market by Type
1.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 AEM-2802
1.2.3 AEM-2814
1.2.4 Alirocumab
1.2.5 Evinacumab
1.2.6 Others
1.3 Market by Application
1.3.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales Estimates and Forecasts 2017-2028
2.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Estimates and Forecasts 2017-2028
2.3 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region
2.4.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2017-2022)
2.4.2 Global Sales Homozygous Familial Hypercholesterolemia Treatment by Region (2023-2028)
2.5 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region
2.5.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2017-2022)
2.5.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Manufacturers
3.1.1 Global Top Homozygous Familial Hypercholesterolemia Treatment Manufacturers by Sales (2017-2022)
3.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Homozygous Familial Hypercholesterolemia Treatment in 2021
3.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Manufacturers
3.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Manufacturers (2017-2022)
3.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Homozygous Familial Hypercholesterolemia Treatment Revenue in 2021
3.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Homozygous Familial Hypercholesterolemia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Homozygous Familial Hypercholesterolemia Treatment Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type
4.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Historical Sales by Type (2017-2022)
4.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Forecasted Sales by Type (2023-2028)
4.1.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2028)
4.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type
4.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Historical Revenue by Type (2017-2022)
4.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Forecasted Revenue by Type (2023-2028)
4.2.3 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2017-2028)
4.3 Global Homozygous Familial Hypercholesterolemia Treatment Price by Type
4.3.1 Global Homozygous Familial Hypercholesterolemia Treatment Price by Type (2017-2022)
4.3.2 Global Homozygous Familial Hypercholesterolemia Treatment Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application
5.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Historical Sales by Application (2017-2022)
5.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Forecasted Sales by Application (2023-2028)
5.1.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2028)
5.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application
5.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Historical Revenue by Application (2017-2022)
5.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Forecasted Revenue by Application (2023-2028)
5.2.3 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2017-2028)
5.3 Global Homozygous Familial Hypercholesterolemia Treatment Price by Application
5.3.1 Global Homozygous Familial Hypercholesterolemia Treatment Price by Application (2017-2022)
5.3.2 Global Homozygous Familial Hypercholesterolemia Treatment Price Forecast by Application (2023-2028)
6 North America
6.1 North America Homozygous Familial Hypercholesterolemia Treatment Market Size by Type
6.1.1 North America Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2028)
6.1.2 North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2017-2028)
6.2 North America Homozygous Familial Hypercholesterolemia Treatment Market Size by Application
6.2.1 North America Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2028)
6.2.2 North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2017-2028)
6.3 North America Homozygous Familial Hypercholesterolemia Treatment Market Size by Country
6.3.1 North America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2028)
6.3.2 North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Homozygous Familial Hypercholesterolemia Treatment Market Size by Type
7.1.1 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2028)
7.1.2 Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2017-2028)
7.2 Europe Homozygous Familial Hypercholesterolemia Treatment Market Size by Application
7.2.1 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2028)
7.2.2 Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2017-2028)
7.3 Europe Homozygous Familial Hypercholesterolemia Treatment Market Size by Country
7.3.1 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2028)
7.3.2 Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Market Size by Type
8.1.1 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2028)
8.1.2 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2017-2028)
8.2 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Market Size by Application
8.2.1 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2028)
8.2.2 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2017-2028)
8.3 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Market Size by Region
8.3.1 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2017-2028)
8.3.2 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Homozygous Familial Hypercholesterolemia Treatment Market Size by Type
9.1.1 Latin America Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2028)
9.1.2 Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2017-2028)
9.2 Latin America Homozygous Familial Hypercholesterolemia Treatment Market Size by Application
9.2.1 Latin America Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2028)
9.2.2 Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2017-2028)
9.3 Latin America Homozygous Familial Hypercholesterolemia Treatment Market Size by Country
9.3.1 Latin America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2028)
9.3.2 Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Market Size by Type
10.1.1 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2028)
10.1.2 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2017-2028)
10.2 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Market Size by Application
10.2.1 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2028)
10.2.2 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2017-2028)
10.3 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Market Size by Country
10.3.1 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2028)
10.3.2 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 CymaBay Therapeutics Inc
11.1.1 CymaBay Therapeutics Inc Corporation Information
11.1.2 CymaBay Therapeutics Inc Overview
11.1.3 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 CymaBay Therapeutics Inc Recent Developments
11.2 Daewoong Co Ltd
11.2.1 Daewoong Co Ltd Corporation Information
11.2.2 Daewoong Co Ltd Overview
11.2.3 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Daewoong Co Ltd Recent Developments
11.3 Gemphire Therapeutics Inc
11.3.1 Gemphire Therapeutics Inc Corporation Information
11.3.2 Gemphire Therapeutics Inc Overview
11.3.3 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Gemphire Therapeutics Inc Recent Developments
11.4 LipimetiX Development Inc
11.4.1 LipimetiX Development Inc Corporation Information
11.4.2 LipimetiX Development Inc Overview
11.4.3 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 LipimetiX Development Inc Recent Developments
11.5 Regeneron Pharmaceuticals Inc
11.5.1 Regeneron Pharmaceuticals Inc Corporation Information
11.5.2 Regeneron Pharmaceuticals Inc Overview
11.5.3 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Regeneron Pharmaceuticals Inc Recent Developments
11.6 RegenxBio Inc
11.6.1 RegenxBio Inc Corporation Information
11.6.2 RegenxBio Inc Overview
11.6.3 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 RegenxBio Inc Recent Developments
11.7 The Medicines Company
11.7.1 The Medicines Company Corporation Information
11.7.2 The Medicines Company Overview
11.7.3 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 The Medicines Company Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Homozygous Familial Hypercholesterolemia Treatment Industry Chain Analysis
12.2 Homozygous Familial Hypercholesterolemia Treatment Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Homozygous Familial Hypercholesterolemia Treatment Production Mode & Process
12.4 Homozygous Familial Hypercholesterolemia Treatment Sales and Marketing
12.4.1 Homozygous Familial Hypercholesterolemia Treatment Sales Channels
12.4.2 Homozygous Familial Hypercholesterolemia Treatment Distributors
12.5 Homozygous Familial Hypercholesterolemia Treatment Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Homozygous Familial Hypercholesterolemia Treatment Industry Trends
13.2 Homozygous Familial Hypercholesterolemia Treatment Market Drivers
13.3 Homozygous Familial Hypercholesterolemia Treatment Market Challenges
13.4 Homozygous Familial Hypercholesterolemia Treatment Market Restraints
14 Key Findings in The Global Homozygous Familial Hypercholesterolemia Treatment Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer